EUPRAXIA PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $1.31 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-13
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.31M 40-F · filed 2026-03-13 | |
| 2024-12-31 | $486.01K 40-F · filed 2026-03-13 | $874.81K 40-F · filed 2025-03-20 |
| 2023-12-31 | $381.29K 40-F · filed 2025-03-20 | |
| 2022-12-31 | $414.72K 40-F · filed 2024-04-01 |